NASDAQ:CSTL Castle Biosciences (CSTL) Stock Price, News & Analysis $14.65 -0.50 (-3.30%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$15.58 +0.93 (+6.34%) As of 08/1/2025 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Castle Biosciences Stock (NASDAQ:CSTL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Castle Biosciences alerts:Sign Up Key Stats Today's Range$14.61▼$15.1650-Day Range$14.65▼$20.4252-Week Range$14.61▼$35.84Volume421,590 shsAverage Volume357,460 shsMarket Capitalization$422.95 millionP/E RatioN/ADividend YieldN/APrice Target$37.00Consensus RatingBuy Company Overview Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas. Read More Castle Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreCSTL MarketRank™: Castle Biosciences scored higher than 63% of companies evaluated by MarketBeat, and ranked 383rd out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCastle Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCastle Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Castle Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Castle Biosciences are expected to decrease in the coming year, from $0.44 to ($1.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Castle Biosciences is -77.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Castle Biosciences is -77.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCastle Biosciences has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Castle Biosciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.88% of the outstanding shares of Castle Biosciences have been sold short.Short Interest Ratio / Days to CoverCastle Biosciences has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Castle Biosciences has recently decreased by 11.88%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCastle Biosciences does not currently pay a dividend.Dividend GrowthCastle Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.88% of the outstanding shares of Castle Biosciences have been sold short.Short Interest Ratio / Days to CoverCastle Biosciences has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Castle Biosciences has recently decreased by 11.88%, indicating that investor sentiment is improving significantly. News and Social Media2.3 / 5News Sentiment0.09 News SentimentCastle Biosciences has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Castle Biosciences this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for CSTL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Castle Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Castle Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.50% of the stock of Castle Biosciences is held by insiders.Percentage Held by Institutions92.60% of the stock of Castle Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Castle Biosciences' insider trading history. Receive CSTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CSTL Stock News HeadlinesExamining the Future: Castle Biosciences's Earnings OutlookAugust 1 at 9:21 PM | benzinga.comCastle Biosciences to Present at the Canaccord Genuity 45th Annual Growth ConferenceJuly 29, 2025 | globenewswire.comOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast. | InvestorPlace (Ad)Castle Biosciences (NASDAQ:CSTL) shareholders have endured a 58% loss from investing in the stock five years agoJuly 27, 2025 | finance.yahoo.comCastle Biosciences stock jumps after FDA grants Breakthrough Device statusJuly 25, 2025 | investing.comCastle Biosciences, Revolution Medicines get FDA breakthrough statusesJuly 25, 2025 | msn.comCastle Biosciences stock jumps after FDA grants Breakthrough Device status to melanoma testJuly 25, 2025 | msn.comCastle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business JournalJuly 25, 2025 | finance.yahoo.comSee More Headlines CSTL Stock Analysis - Frequently Asked Questions How have CSTL shares performed this year? Castle Biosciences' stock was trading at $26.65 at the beginning of 2025. Since then, CSTL stock has decreased by 45.0% and is now trading at $14.65. How were Castle Biosciences' earnings last quarter? Castle Biosciences, Inc. (NASDAQ:CSTL) announced its quarterly earnings data on Monday, May, 5th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.12. The firm earned $87.99 million during the quarter, compared to analysts' expectations of $80.40 million. Castle Biosciences had a negative net margin of 1.46% and a positive trailing twelve-month return on equity of 3.41%. Read the conference call transcript. When did Castle Biosciences IPO? Castle Biosciences (CSTL) raised $50 million in an initial public offering (IPO) on Thursday, July 25th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Baird acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. Who are Castle Biosciences' major shareholders? Castle Biosciences' top institutional investors include Allianz Asset Management GmbH (2.47%), Allspring Global Investments Holdings LLC (0.56%), Y Intercept Hong Kong Ltd (0.27%) and Envestnet Asset Management Inc. (0.24%). Insiders that own company stock include Kristen M Oelschlager, Derek J Maetzold, Tobin W Juvenal, Frank Stokes, Ellen Goldberg, Tiffany Olson and Daniel Bradbury. View institutional ownership trends. How do I buy shares of Castle Biosciences? Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Castle Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Castle Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), PayPal (PYPL), Adobe (ADBE), Advanced Micro Devices (AMD) and Broadcom (AVGO). Company Calendar Last Earnings5/05/2025Today8/02/2025Next Earnings (Estimated)8/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryHealthcare Current SymbolNASDAQ:CSTL CIK1447362 Webcastlebiosciences.com Phone(866) 788-9007FaxN/AEmployees540Year FoundedN/APrice Target and Rating Average Price Target for Castle Biosciences$37.00 High Price Target$41.00 Low Price Target$30.00 Potential Upside/Downside+152.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.19) Trailing P/E RatioN/A Forward P/E Ratio33.30 P/E GrowthN/ANet Income$18.25 million Net Margins-1.46% Pretax Margin-0.64% Return on Equity3.41% Return on Assets2.95% Debt Debt-to-Equity Ratio0.02 Current Ratio9.37 Quick Ratio9.19 Sales & Book Value Annual Sales$332.07 million Price / Sales1.27 Cash Flow$0.95 per share Price / Cash Flow15.40 Book Value$16.28 per share Price / Book0.90Miscellaneous Outstanding Shares28,870,000Free Float26,995,000Market Cap$422.95 million OptionableOptionable Beta1.09 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:CSTL) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Castle Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.